<- Go home

Added to YB: 2026-02-18

Pitch date: 2026-02-14

CPH.TO [neutral]

Cipher Pharmaceuticals Inc.

+31.39%

current return

Author Info

Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.

Company Info

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

Market Cap

CAD 330.8M

Pitch Price

CAD 14.56

Price Target

N/A

Dividend

N/A

EV/EBITDA

13.65

P/E

12.45

EV/Sales

6.52

Sector

Pharmaceuticals

Category

growth

Show full summary:
CPH Update

CPH.TO (update): Canadian pharma w/ Epuris, Absorica, Natroba (head lice). Post-ParaPRO acquisition transforming business. Est. steady-state ~$55M rev, $25-30M EBITDA. Natroba expansion (Canada approval pending, US growth, global out-licensing potential), Absorica in-house 2027 (Sun arbitration ongoing). Trading ~10x EV/EBITDA vs potential upside from market share gains, geographic expansion, optionality on MOB-015 nail fungus, CF-101 psoriasis. Risks: Natroba stalls, Absorica transition, arbitration loss.

Read full article (7 min)